Roivant Sciences' Gline proposes $6.73M share sale

The securities are identified as performance stock units acquired from the issuer for services rendered on November 10, 2026.

Available on EDGAR 11/10/2026 - 05:08 PM EST Accepted by SEC EDGAR 11/10/2026 - 05:07 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Roivant Sciences Ltd. officer and director Matthew Adam Gline reported 164,136 common shares for sale, with an aggregate market value of $6,729,576.00 and an approximate sale date of November 10, 2026. The shares are being sold automatically under a mandatory, non-discretionary sell-to-cover arrangement adopted by the issuer to satisfy tax withholding obligations incurred upon the vesting and settlement of equity awards.

Key Figures

Common shares to be sold: 164,136 shares Aggregate market value: $6,729,576.00 Common shares outstanding: 724,561,460 shares

3 metrics

Common shares to be sold 164,136 shares Approximate sale date: November 10, 2026

Aggregate market value $6,729,576.00 Securities reported for sale

Common shares outstanding 724,561,460 shares Securities information

Key Terms

Performance Stock Units, sell-to-cover arrangement, tax withholding obligations, vesting and settlement

4 terms

Performance Stock Units financial

"Nature of Acquisition Transaction: Performance Stock Units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

sell-to-cover arrangement financial

"mandatory, non-discretionary, sell-to-cover arrangement"

tax withholding obligations financial

"satisfying tax withholding obligations incurred upon the vesting"

vesting and settlement financial

"upon the vesting and settlement of equity awards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares is Matthew Adam Gline reporting for sale?

Matthew Adam Gline reported 164,136 common shares for sale, with an aggregate market value of $6,729,576.00 and an approximate sale date of November 10, 2026.

How did Matthew Adam Gline acquire the ROIV shares?

The securities were listed as performance stock units acquired from the issuer for services rendered on November 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0001750094
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001950047-26-010941
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	ROIVANT SCIENCES LTD.
SEC File Number	001-40782
Address of Issuer	50 Broadway London UNITED KINGDOM SW1H 0DB
Phone	44 207 400 3347
Name of Person for Whose Account the Securities are To Be Sold	MATTHEW ADAM GLINE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	164136	6729576.00	724561460	11/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/10/2026	Performance Stock Units	Issuer			164136	11/10/2026	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report

144/A: Remarks and Signature

Remarks	We are amending this filing to add the following remarks: The Shares covered by this Form 144 are being sold automatically pursuant to a mandatory, non-discretionary, sell-to-cover arrangement adopted by the Issuer for the purpose of satisfying tax withholding obligations incurred upon the vesting and settlement of equity awards.
Date of Notice	11/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Matthew Adam Gline
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)